Bioequivalence of a Fixed-Dose Combination Tablet of the Complete 2-Drug Regimen Dolutegravir and Rilpivirine for the Treatment of HIV-1 Infection.

Conclusions: The dolutegravir/rilpivirine fixed-dose combination tablet is bioequivalent to a combination of separate tablets and no new safety signals emerged.
PMID: 29987139 [PubMed - as supplied by publisher]

Source: Antimicrobial Agents and Chemotherapy - July 9, 2018 Category: Microbiology Authors: Mehta R, Wolstenholme A, Di Lullo K, Fu C, Joshi S, Crauwels H, Givens N, Vanveggel S, Wynne B, Adkison K Tags: Antimicrob Agents Chemother Source Type: research